Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Dexamethasone + Evofosfamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Evofosfamide||TH-302||Chemotherapy - Alkylating 14||Evofosfamide (TH-302) is a hypoxia-activated prodrug that releases a DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors, potentially providing antineoplastic activity with reduced systemic toxicity (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Dexamethasone + Evofosfamide||Phase Ib/II||Actionable||In a Phase I/II trial, Evofosfamide (TH-302) therapy plus Adexone (dexamethasone) was well tolerated in patients with relapsed/refractory multiple myeloma and resulted in a disease control rate of 83.9% (26/31, stable disease or better), 3.3% (1/31) very good partial responses and 9.7% (3/31) partial responses, a 40% 6-month progression-free survival rate, a median progression-free survival of 4.4 months, and a median overall survival of 12.8 months (PMID: 30279233; NCT01522872).||30279233|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|